Skip to main content
    B

    Biohaven Ltd. (BHVN)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NYSE

    $14.47
    +0.57 (+4.10%)

    Market Cap: $2.10B

    Last updated: Nov 06, 2026 at 4:20 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    21%(8/39)
    Avg Surprise
    -33.87%

    Upcoming Estimates

    Period ending Dec 31, 2026
    EPS Consensus$0.04
    Range$-1.63 - $1.16
    5 analysts
    Revenue Consensus
    $92M
    Range$-50000000 - $380M
    14 analysts
    Period ending Mar 31, 2027
    EPS Consensus$-0.46
    Range$-0.46 - $-0.46
    1 analysts
    EPS RevisionsNo revisions (7d)
    0
    1
    30d
    EPS Estimate DriftChange to current
    90d ago$-0.53+13.2%
    60d ago$-0.51+9.8%
    30d ago$-0.51+9.8%
    7d ago$-0.460.0%
    Current$-0.46
    Revenue Consensus
    $12M
    Range$0 - $70M
    6 analysts
    Last 12 of 40 reported quarters and 2 upcoming estimates
    PeriodReportedEst.RangeSurpriseB/MAnalystsRevisionsYoY
    Mar 27EST
    		-$-0.46$-0.46 - $-0.46--1
    0
    1
    30d
    		-
    Dec 26EST
    		-$0.04$-1.63 - $1.16--5--
    Sep 26
    Reported Oct 29
    		$-0.86$-0.80$-1.69 - $0.70-7.50%Miss6
    1
    2
    30d
    		+41.5%
    Jun 26
    Reported Aug 10
    		$-0.91$-0.77$-0.77 - $-0.44-18.18%Miss8
    3
    3
    30d
    		+44.2%
    Mar 26
    Reported May 4
    		$-0.69$-0.76$-1.07 - $-0.61+9.21%Beat6
    2
    2
    30d
    		+57.9%
    Dec 25
    Reported Mar 2
    		$-0.90$-1.18$-1.21 - $-0.36+23.73%Beat5
    1
    0
    30d
    		+47.4%
    Sep 25
    Reported Nov 10
    		$-1.47$-1.54$-1.80 - $-1.43+4.55%Beat6
    0
    3
    30d
    		+15.5%
    Jun 25
    Reported Aug 11
    		$-1.63$-1.57$-2.32 - $-1.17-3.82%Miss4
    1
    1
    30d
    		+53.4%
    Mar 25
    Reported May 12
    		$-1.64$-1.47$-1.70 - $-1.19-11.56%Miss4
    1
    0
    30d
    		+7.3%
    Dec 24
    Reported Mar 3
    		$-1.71$-1.60$-1.75 - $-0.90-6.88%Miss5
    No revisions (30d)
    		+5.5%
    Sep 24
    Reported Nov 12
    		$-1.74$-1.55$-2.19 - $-1.30-12.26%Miss13
    1
    0
    30d
    		-16.0%
    Jun 24
    Reported Aug 8
    		$-3.50$-1.70$-2.44 - $-1.28-105.88%Miss12
    No revisions (30d)
    		-165.2%
    Mar 24
    Reported May 9
    		$-1.77$-1.62$-1.97 - $-1.27-9.26%Miss10
    No revisions (30d)
    		-71.8%
    Dec 23
    Reported Feb 29
    		$-1.81$-1.41$-1.62 - $-1.14-28.37%Miss11
    No revisions (30d)
    		+45.5%

    Key Metrics

    Valuation
    P/E Ratio-4.31EV/EBITDAN/A
    Price/FCF-4.62xFCF Yield-21.65%
    Profitability
    Profit Margin0.00%Operating Margin0.00%
    ROE-799.00%ROIC-315.86%
    Financial Health
    Debt/Equity-2.69xInterest CoverageN/A
    Current Ratio3.05xQuick Ratio3.05x
    Trading Statistics
    Beta3.13Avg Volume3.60M
    52-Week High$18.2452-Week Low$7.48

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$15.15
    SMA 20$13.57
    SMA 50$13.61
    SMA 200$12.28
    EMA 10$14.64
    EMA 20$14.14
    EMA 50$13.74
    EMA 200$13.15

    MACD

    Line: 0.56Signal: 0.47Hist: 0.09

    ADX

    ADX: 29.0+DI: 24.9-DI: 20.4

    Aroon & PSAR

    Aroon Up56.0
    Aroon Down40.0
    PSAR$13.62

    Bollinger Bands

    Upper Band$17.40
    Lower Band$9.74
    %B Position5643%(Upper)
    Band Width0.62

    RSI (14-Day)

    Neutral
    53.2

    Momentum Oscillators

    Stoch %K64.5
    Stoch %D71.9
    Williams %R-37.8
    ROC (10d)4.3%
    Momentum0.59
    CCI (20d)23.4
    MFI (14d)68.8

    Volatility Measures

    ATR (14d)$1.08(7.4%)
    StdDev (20d)1.91
    Hist Vol115.6%(High)

    Volume Flow

    VWAP$14.24
    OBV-18.2M
    AD Line-75.0M
    CMF (20d)-0.391

    Volume Metrics

    Avg Vol (20d)3.8M
    Vol Ratio0.5x(Low)
    VWMA (20d)$14.15

    Pivot Points

    R3$16.00
    R2$15.55
    R1$14.73
    Pivot Point$14.28
    S1$13.46
    S2$13.01
    S3$12.19

    Advanced Oscillators

    TSI13.41
    Ultimate Osc41.7
    KST170.94

    Financial Data

    QuarterSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Total Revenue$0$0$0$0$0$0$0$3.84M$0$0$0$0
    Cost of Revenue$0$0$0$960,000$0$0$0$1.92M$0$0$0$948,000
    Gross Profit$0$0$0$-960,000$0$0$0$1.92M$0$0$0$-948,000
    Operating Expenses$126.42M$124.90M$130.43M$142.73M$169.38M$211.70M$221.56M$189.93M$178.17M$333.77M$183.24M$153.71M
    R&D$101.85M$100.81M$103.83M$121.94M$141.17M$184.37M$187.58M$167.47M$157.61M$314.82M$155.97M$134.81M
    SG&A$24.57M$24.09M$26.60M$20.79M$28.21M$27.33M$33.98M$22.46M$20.56M$18.95M$27.27M$18.90M
    Operating Income$-126,420,000$-124,899,000$-130,428,000$-142,734,000$-169,382,000$-211,701,000$-221,561,000$-189,931,000$-178,168,000$-333,772,000$-183,240,000$-153,711,000
    Interest Income$0$0$0$0$0$0$0$0$0$0$0$0
    Interest Expense$2.92M$12.02M$0$2.47M$3.84M$0$0$0$0$0$0$0
    Income Before Tax$-129,343,000$-136,920,000$-130,260,000$-145,204,000$-173,222,000$-197,886,000$-221,068,000$-186,795,000$-160,363,000$-319,594,000$-178,935,000$-145,968,000
    Income Tax Expense$-64,000$391,000$272,000$351,000$221,000$261,000$609,000$48,000$-59,000$177,000$569,000$-1,212,000
    Net Income$-129,279,000$-137,311,000$-130,532,000$-145,555,000$-173,443,000$-198,147,000$-221,677,000$-186,843,000$-160,304,000$-319,771,000$-179,504,000$-144,756,000
    EBITDA$-124,196,000$-122,640,000$-128,062,000$-140,161,000$-166,257,000$-209,723,000$-219,315,000$-187,470,000$-176,174,000$-331,818,000$-177,489,000$-144,074,000
    EBIT$-126,420,000$-124,899,000$-130,428,000$-142,734,000$-169,382,000$-211,701,000$-221,561,000$-189,931,000$-178,168,000$-333,772,000$-178,935,000$-145,968,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about BHVN

    News

    Biohaven Ltd. Stock 12‑Month Price Target Raised to $25.67, Implies 56% Upside

    Biohaven Ltd.'s average 12-month price target has been raised by analysts from $25.17 to $25.67, with forecasts ranging from $9 to $48 per share. This updated target suggests a potential upside of approximately 56% from...

    TradingView•10/31/26•Bullish

    Earnings Flash (BHVN) Biohaven Ltd. Posts Q3 Adjusted Loss $0.73 per Share, Vs. FactSet Est of $-0.78

    Biohaven Ltd. (BHVN) announced an adjusted loss of $0.73 per share for the third quarter, which was better than the FactSet estimate of a $0.78 per share loss. This earnings report provides key financial performance data...

    Moomoo•10/30/26•Somewhat-Bullish

    Biohaven Ltd. Stock 12‑Month Price Target Raised to $25.67, Implies 56% Upside

    Biohaven Ltd. (BHVN) has seen its average price target raised from $25.17 to $25.67 by 12 analysts, implying a potential 56% upside based on the October 29 closing price. The consensus rating for the stock remains "Buy,"...

    TradingView•10/30/26•Bullish

    Biohaven Reports Q3 2026 Results and $400 Million Kv7 License Agreement

    Biohaven reported a Q3 2026 net loss of $129.3 million, or $0.86 per share, an improvement from $173.4 million a year earlier. The company also announced an exclusive global license agreement with SK Biopharmaceuticals...

    TradingView•10/29/26•Somewhat-Bullish

    Form 10-Q Biohaven Ltd. For: Sep 30

    Biohaven Ltd. filed its Form 10-Q for the quarter ended September 30, 2026, detailing its financial condition and results of operations. The company reported a net loss of $129.279 million for the three months ended...

    StreetInsider•10/29/26•Somewhat-Bullish

    BHVN Valuation and Fair Value

    P/E
    -4.3x
    P/FCF
    -4.6x
    P/B
    -22.2x
    See GNG's fair value

    BHVN Profitability: Margins, ROIC and FCF

    Operating margin
    0.0%
    Net margin
    0.0%
    ROIC
    -315.9%
    ROE
    -799.0%
    FCF yield
    -21.6%

    BHVN Competitors

    CompanyTicker
    BioCryst Pharmaceuticals IncBCRX
    Prestige Brand Holdings IncPBH
    Dynavax Technologies CorporationDVAX
    Avadel Pharmaceuticals PLCAVDL
    NeoGenomics IncNEO
    Select Medical HoldingsSEM
    Schrodinger IncSDGR
    Dentsply Sirona IncXRAY

    Sector: Healthcare

    BHVN Analyst Ratings

    Consensus
    Buy
    Analysts
    17
    Strong Buy
    3
    Buy
    9
    Hold
    4
    Sell
    0
    Strong Sell
    1

    BHVN Bull Case vs Bear Case

    Bull case

    • 70.6% of BHVN's analyst ratings are Buy or Strong Buy.

    Bear case

    • BHVN beat EPS estimates in 37.5% of its last 8 reported quarters.

    BHVN Earnings: Beat Rate and Next Report

    Beat rate
    3 of 8 quarters (37.5%)
    Average surprise
    -1.3%
    EPS estimate (fiscal period ending Dec 31, 2026)
    $0.04

    BHVN Earnings Date

    BHVN reports Mar 1, 2027, after the close. The date is confirmed.

    BHVN ETF Holders

    GNG tracks 7 ETFs that hold BHVN. The largest weights:

    1. State Street SPDR S&P Biotech ETF (XBI), 0.56% of the fund
    2. iShares Biotechnology ETF (IBB), 0.14% of the fund
    3. Fidelity Enhanced Small Cap Core ETF (FESM), 0.08% of the fund
    4. iShares Russell 2000 ETF (IWM), 0.04% of the fund
    5. Vanguard Russell 2000 Index Fund ETF Shares (VTWO), 0.03% of the fund
    Open the ETF Stock Exposure tool for BHVN

    Frequently Asked Questions About BHVN

    When does BHVN report earnings?

    Biohaven Ltd. (BHVN) is confirmed to report earnings on Mar 1, 2027.

    Does BHVN pay dividends?

    Biohaven Ltd. (BHVN) does not currently pay a regular dividend.

    What is BHVN's market cap?

    Biohaven Ltd. (BHVN) has a market capitalization of $2.10B with a current stock price of $14.47.

    Related stocks

    Sector: Healthcare

    All stocks starting with B

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In